Citation Impact
Citing Papers
Multiple Biomarkers for Risk Prediction in Chronic Heart Failure
2012
Vitamin D Deficiency and Risk of Cardiovascular Disease
2008 Standout
Effective treatment of severe COVID-19 patients with tocilizumab
2020 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
2014 Standout
Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide
2004
Heart Failure Outcomes and Benefits of NT-proBNP-Guided Management in the Elderly: Results From the Prospective, Randomized ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study
2012
Rising Incidence of Renal Cell Cancer in the United States
1999 Standout
The prevention of heart failure in minority communities and discrepancies in health care delivery systems
2004
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
2008 Standout
Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure
1992
Acute kidney injury
2012 Standout
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
2010 Standout
The paradox of low BNP levels in obesity
2011
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
2005 Standout
N-Terminal Pro–B-Type Natriuretic Peptide–Guided, Intensive Patient Management in Addition to Multidisciplinary Care in Chronic Heart Failure
2010
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
2006 Standout
Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension*
2005
Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure
2004
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Treatment of Pulmonary Arterial Hypertension
2004 Standout
Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: A randomized, double-blind, placebo-controlled study
1998
Valsartan in heart failure patients previously untreated with an ACE inhibitor
1998
B-type natriuretic peptide in cardiovascular disease
2003
Acute Cardiac Tamponade
2003 Standout
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
2007
Surgical Correction of Renovascular Hypertension
1988
Levels of sP-selectin and hs-CRP Decrease with Dietary Intervention with Selenium and Coenzyme Q10 Combined: A Secondary Analysis of a Randomized Clinical Trial
2015 StandoutNobel
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A–deficient mice
2001 StandoutNobel
The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure
2005 Standout
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin
2001
NT-ProBNP Reduction Percentage During Admission for Acutely Decompensated Heart Failure Predicts Long-Term Cardiovascular Mortality
2005
The Prognostic Value of Big Endothelin-1 in More Than 2,300 Patients With Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT)
2006
Fibromuscular Dysplasia
2004 Standout
Hormones and Hemodynamics in Heart Failure
1999
Successes and failures of current treatment of heart failure
1998
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
2003 Standout
Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
2002 Standout
Endothelin antagonists
1999
Effect of Carvedilol on Survival in Severe Chronic Heart Failure
2001 Standout
Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay
2001 Standout
Natriuretic Peptides
2007
Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial
2006
Percutaneous transluminal renal angioplasty: Initial results and long-term follow-up in 202 patients
1990
Rationale for Fixed-Dose Combinations in the Treatment of Hypertension
2002
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure
2003
Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data
2006
Congestive Heart Failure: Fifty Years of Progress
2000
Seven-transmembrane-spanning receptors and heart function
2002 StandoutNatureNobel
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2014 Standout
Right ventricular cardiomyopathy in β-thalassaemia major
2002
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
1999 Standout
Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet
2001 Standout
N-Terminal Pro-Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels as Predictors of Mortality and Cardiovascular Events in Older Adults
2005
Interleukin-6 and its receptors: A highly regulated and dynamic system
2014
Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure
2007
Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting–Enzyme Inhibitor in Normotensive and Hypertensive Subjects
1998
Biomarkers in Heart Failure
2008 Standout
Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with Placebo
1993
Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease<SUBTITLE>Results From the AASK Trial</SUBTITLE>
2002 Standout
Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials
1999
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
2010 Standout
Interleukin-6 Signaling, Soluble Glycoprotein 130, and Inflammation in Heart Failure
2014
Prognostic value of serial B‐type natriuretic peptide measurement in asymptomatic organic mitral regurgitation
2010
Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction
2007
N‐terminal probrain natriuretic peptide (NT‐proBNP) in the emergency diagnosis and in‐hospital monitoring of patients with dyspnoea and ventricular dysfunction
2004
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 Standout
HIF-1α is required for development of the sympathetic nervous system
2019 StandoutNobel
Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure
1999 Standout
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Cardioselective beta-blockers for chronic obstructive pulmonary disease
2005
Exercise and Heart Failure
2003
The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment
2003
Transcatheter Mitral-Valve Repair in Patients with Heart Failure
2018 Standout
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
Overexpression of angiotensin AT 1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block
1997 StandoutNobel
Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death
2004
A Comparison of the Efficacy and Safety of a β-Blocker, a Calcium Channel Blocker, and a Converting Enzyme Inhibitor in Hypertensive Blacks
1990
Mobilized bone marrow cells repair the infarcted heart, improving function and survival
2001 Standout
Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
2009
Natriuretic Peptides Predict Symptom-Free Survival and Postoperative Outcome in Severe Aortic Stenosis
2004
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Angiotensin-Converting Enzyme Inhibitors
1998
Influence of Race and Dietary Salt on the Antihypertensive Efficacy of an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Antagonist in Salt-Sensitive Hypertensives
1998
Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device
2009 Standout
Epidemiology and Genetics of Sudden Cardiac Death
2012
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Exercise and Physical Activity in the Prevention and Treatment of Atherosclerotic Cardiovascular Disease
2003 Standout
Cardiovascular drugs in children: Angiotensin-converting enzyme inhibitors
1988
Secondary Pulmonary Hypertension in Chronic Heart Failure
2000
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
2010 Standout
Treatment of Periodontitis and Endothelial Function
2007 Standout
Increased Plasma Natriuretic Peptide Levels Reflect Symptom Onset in Aortic Stenosis
2003
Works of Brigitte Stanek being referenced
Comparison of Soluble Glycoprotein 130 and Cardiac Natriuretic Peptides as Long-term Predictors of Heart Failure Progression
2005
Moderate-intensity exercise training with elements of step aerobics in patients with severe chronic heart failure
1999
Long-term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction
2001
Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
1996
Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period
2003
Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction
2001
Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure
2004
Sudden Death and Staged Therapy for Hemodynamic Stabilization in Patients Enrolled in a Heart Transplantation Program
1995
Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure
1996
Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure
1998
Effect of β1 blockade with atenolol on progression of heart failure in patients pretreated with high‐dose enalapril
2000
B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure
2002
Effects of Endothelin A Receptor Blockade on Endothelial Function in Patients With Chronic Heart Failure
2001
Acute and Chronic Effects of Captopril on Bicyclo-PGEm, the Stable Bicyclic End Product of Prostaglandin E<sub>2</sub> in Essential Hypertension
1986
Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure.
1998
Racial differences in response to low‐dose captopril are abolished by the addition of hydrochlorothiazide.
1982
Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide.
1982
Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.
1982
Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables.
1998